Dendreon Shares Soar on Provenge Data

The survival benefit at the interim analysis announced Monday was actually lower than the company had predicted when it designed the IMPACT study. This means that for the final analysis of the IMPACT study to be successful and statistically significant, the net survival benefit for those Provenge patients remaining in the study will have to be greater than the Provenge patients who have already died.

This feat could prove challenging given changes made by Dendreon earlier this year to accelerate the timing of the final analysis of the IMPACT study.